oncology

Enhertu tops standard care in first-line HER2 lung cancer trial

AstraZeneca and Daiichi Sankyo announced on Monday that their antibody drug conjugate Enhertu demonstrated a statistically significant improvement in progression-free survival over the current global standard of care as a first-line treatment for patients with HER2-mutant advanced lung cancer, marking…

Scientists publish largest cancer model compendium in Nature

An international team of scientists has unveiled one of the most extensive collections of patient-derived cancer models to date, offering researchers new tools to study tumor biology and accelerate the development of personalized treatments. The compendium, published Wednesday in Nature,…

Mayo Clinic identifies protein that cancers use to evade immune system

Mayo Clinic researchers have discovered how cancer cells exploit a protein variant called TRAILshort to shut down the body's immune defenses, a finding that could reshape approaches to immunotherapy across a range of cancers and chronic infections.

Study finds inherited genes steer how DNA damage becomes cancer

A sweeping international study published in Nature on July 22 has provided the first direct evidence that a person's inherited genetic makeup can determine how DNA damage from environmental exposures leads to cancer — and how that cancer evolves over…

WHO report finds vast gap in breast cancer survival

The World Health Organization published the first-ever global breast cancer survival estimates on July 8, showing that a woman's chance of surviving the disease depends heavily on where she lives and how much her country earns. The data, released alongside…

Scientists find 81 hidden genes driving deadly breast cancer

A team of scientists at Sinai Health in Toronto has uncovered 81 previously unknown genes involved in basal-like triple-negative breast cancer, solving a long-standing mystery of how chromosomal chaos fuels one of the disease's deadliest forms. The findings, published in…

First international patient treated with China’s solid tumor CAR-T therapy

Jiahui International Cancer Center in Shanghai announced on July 6 that it has begun treating the world's first international patient with Satri-cel, the recently approved CAR-T cell therapy for solid tumors. The milestone comes just two weeks after China's National…

Novartis to buy UK biotech Myricx Bio for up to $1.5B

Novartis announced on Monday it has agreed to acquire UK-based biotechnology firm Myricx Bio for up to $1.5 billion, adding a novel cancer drug platform to its oncology pipeline as competition intensifies in the antibody-drug conjugate space.

Harvard AI model predicts which cancer patients will respond to immunotherapy

Researchers at Harvard Medical School have developed an artificial intelligence model called COMPASS that can predict which cancer patients will respond to immune checkpoint inhibitors, a class of drugs that works in only a fraction of those who receive them.…

New CAR-T therapy shows early success against solid tumors

Researchers at the University of Calgary's Charbonneau Cancer Institute and McMaster University have developed GCAR1, a first-in-class chimeric antigen receptor T-cell therapy designed to attack solid tumors — a category of cancer that has largely resisted the immunotherapy approach until…

FDA approves Trodelvy for first-line metastatic breast cancer

The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences' Trodelvy (sacituzumab govitecan-hziy) for the first-line treatment of metastatic triple-negative breast cancer, a decision that establishes the antibody-drug conjugate as a new standard of care for one of the…

China approves world’s first CAR-T therapy for solid tumors

China's National Medical Products Administration on Monday approved CARsgen Therapeutics' satricabtagene autoleucel, marking the first regulatory approval anywhere in the world for a CAR-T cell therapy targeting solid tumors. The treatment, also known as satri-cel, is indicated for patients with…